Kamada Ltd. (NASDAQ:KMDA) Q3 2022 Earnings Call Transcript

Amir London : Yes. So, of course, we are focusing on the larger ones. We’re focusing on the one that are using our products and we’d like increase usage. We are also talking to centers that have not used, especially CYTOGAM in recent years. And as I said, those products were not supported by field activity. So, now it’s a good change in terms of the ability to grow the business and to promote it and to talk to physicians and to collect data and present the data to the physicians. So, all of this is actually happening as we speak with our U.S. team. In terms of , we’re talking about 150 to 200 centers that we are covering. It’s a very focused effort with the focused team of experienced specialist and it’s going very well in terms of our coverage and our ability to talk to the right people.

Bob Yedid: Great. And just going back to, we talked obviously about success of your acquired portfolio of products, does Kamada have an ongoing or excuse me, business development effort to continue to look for products like this to continue to expand your portfolio of proprietary products?

Amir London: We are building the right infrastructure. As I said, we’re highly focused on specialty plasma products and transportation centers. And in parallel to that, we will be looking and we’ve started to look at what might be another synergistic product, but from a BD perspective, we can bring in, this is an effort that will take us through 2023 and we will be looking for the right opportunities.

Bob Yedid: Great. Okay, great. That’s all the questions we have from the , so that was very helpful. Rob, I’ll turn it back to you.

Operator: Thank you. Thank you. At this time, I’ll turn the floor over to Amir London for closing remarks.

Amir London: Thank you very much. So, in closing, we begin to realize the significant benefits of our recent strategic transformation. Our strong third quarter performance is consistent with our forecast as a positive outlook. Based on expectation for continued revenue growth and enhanced profitability in the fourth quarter, we are reiterating our full-year 2022 financial guidance. As discussed during the call, we continue to focus growth at the double-digit rate in the foreseeable years ahead of us, driven by our proprietary product categories. We thank all our investors for their support and remain extremely committed to creating long-term sustainable shareholder value. Thank you very much. We hope you all stay healthy and safe.

Operator: This will conclude today’s conference. You may disconnect your lines at this time and thank you for your participation.